Načítá se...
HCV Replicon Systems: Workhorses of Drug Discovery and Resistance
The development of direct-acting antivirals (DAAs) has revolutionized the state-of-the art treatment of HCV infections, with sustained virologic response rates above 90%. However, viral variants harboring substitutions referred to as resistance-associated substitutions (RASs) may be present in basel...
Uloženo v:
| Hlavní autoři: | , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Frontiers Media S.A.
2020-06-01
|
| Edice: | Frontiers in Cellular and Infection Microbiology |
| Témata: | |
| On-line přístup: | https://www.frontiersin.org/article/10.3389/fcimb.2020.00325/full |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|